The Lancet has published full results of a Phase II trial showing the benefit of Lilly’s JAK inhibitor Olumiant in the treatment of global systemic lupus erythematosus (SLE). More: Lilly to progress Olumiant into PhIII for lupus Source: News
read moreEli Lilly is teaming up with Anima Biotech in an exclusive collaboration to discover and develop translation inhibitors for several protein targets. More: Lilly links with Anima Source: News
read moreAstraZeneca is selling rights to its heart failure and hypertension brand Atacand in Europe, in a move that it says will expand its commercial potential in 28 countries. More: AstraZeneca sells Atacand rights to Cheplapharm Source: News
read moreUS regulatory advisors are questioning the effectiveness of GlaxoSmithKline’s biologic Nucala as a treatment for patients experiencing a sudden worsening of chronic obstructive pulmonary disorder (COPD). More: FDA staff question efficacy of GSK’s Nucala for COPD Source: News
read moreAgios Pharmaceuticals has scored its first FDA nod for a wholly-owned medicine, Tibsovo. More: Agios wins FDA nod for targeted AML drug Tibsovo Source: fierce
read moreRoche joined a growing list of Big Pharma companies calling a halt to drug price increases—or cutting them—after President Donald Trump’s naming and shaming. But that was after the Swiss drugmaker had already put through two rounds of price hikes
read more© 1994 - 2026 B.M. Pharmaceuticals